lignan
import
compon
food
medicin
biosynthet
deriv
radic
coupl
two
molecul
coniferyl
alcohol
posit
figur
classifi
differ
dihydroxybenzylbutan
dibenzylbutyrolactol
dibenzylbutyrolacton
aryltetralin
lacton
arylnaphtalen
basi
skeleton
oxid
way
oxygen
incorpor
skeleton
figur
podophyllotoxin
deoxypodophyllotoxin
perhap
import
biolog
activ
lignan
properti
broadli
review
last
year
biolog
activ
sever
lignan
studi
depth
among
hinokinin
emerg
new
interest
compound
aim
review
examin
hinokinin
phytochem
biolog
point
view
peerreview
articl
hinokinin
acquir
via
scopu
scifind
pubm
databas
hinokinin
figur
isol
first
time
yoshiki
ishiguro
ether
extract
hinoki
wood
chamecypari
obtusa
sieb
et
zucc
colorless
crystallin
compound
later
mame
brigg
keimatsu
establish
ident
hinokinin
cubebinolid
haworth
woodcock
determin
tran
configur
lacton
ring
synthesi
biosynthesi
hinokinin
recent
studi
linum
corymbulosum
reichenb
bayindir
et
al
start
observ
callu
cultur
l
corymbulosum
accumul
accord
lignan
composit
found
chamaecypari
obtusa
takaku
author
propos
two
differ
pathway
biosynthesi
hinokinin
start
pinoresinol
scheme
first
pathway
pinoresinol
reduc
secoisolariciresinol
pinoresinollariciresinol
reductas
follow
format
methylenedioxi
bridg
second
pathway
format
methylenedioxi
bridg
pinoresinol
give
sesamin
latter
convert
dihydrocubebin
hinokinin
isol
enzym
respons
enantiospecif
convers
pinoresinol
secoisolariciresinol
establish
first
pathway
oper
hinokinin
biosynthesi
first
isol
c
obtusa
hinokinin
isol
c
formonensi
sever
plant
exampl
zanthoxylum
simulan
z
naranjillo
z
lemairi
z
monophyllum
z
pistaciiflorum
z
ailanthoid
also
found
differ
speci
phyllanthu
aristolochia
piper
virola
linum
anoth
genu
produc
hinokinin
bursera
compound
found
b
cuneata
b
citronella
koulman
b
simaruba
maldini
et
al
hinokinin
found
compon
sever
cytotox
extract
petroleum
ether
fraction
ethanol
extract
zanthoxylum
ailanthoid
sieb
zucc
stem
bark
cytotox
hinokinin
investig
sever
author
differ
cancer
line
murin
lymphocyt
leukemia
human
colon
adenocarcinoma
human
lung
adenocarcinoma
human
breast
adenocarcinoma
ikeda
et
al
test
hinokinin
isol
anthriscu
sylvestri
murin
metastat
melanoma
hela
human
cervic
cancer
murin
gastric
adenocarcinoma
cell
line
use
diphenyltetrazolium
bromid
mtt
microcultur
assay
result
report
tabl
hinokinin
also
examin
antitumor
promot
agent
human
cytomegaloviru
hcmv
immedi
earli
ie
antigen
express
human
lung
adenocarcinoma
cell
establish
dose
caus
inhibit
cell
line
author
found
abl
reduc
ie
antigen
express
hcmvinfect
lung
cancer
cell
dosedepend
manner
reduct
respect
accord
suff
pezzuto
pure
compound
consid
antitumor
activ
show
valu
less
point
view
hinokinin
could
regard
antitumor
compound
hela
cell
line
mansoor
et
al
evalu
apoptosi
induct
hinokinin
human
hepatoma
cell
hinokinin
significantli
reduc
viabil
cell
show
strong
induc
apoptosi
induc
increas
apoptot
cell
compar
control
furthermor
hinokinin
found
highli
toxic
use
brine
shrimp
letal
test
bst
recent
awal
et
al
studi
cytotox
sever
lignan
isol
w
indica
cancer
cell
line
human
pancreat
cancer
found
hinokinin
well
lignan
arctigenin
stereochemistri
inact
cell
line
wherea
enantiom
cytotox
result
indic
absolut
configur
enantiom
requir
cytotox
hinokinin
result
ineffect
nasopharyng
carcinoma
gastric
adenocarcinoma
cell
line
well
known
inflamm
key
event
cancer
develop
reason
nowaday
antiinflammatori
activ
natur
compound
broadli
studi
hinokinin
shown
potent
inhibitori
compound
human
neutrophil
superoxid
gener
elastas
releas
neutrophil
inhibitori
percentag
respect
diphenyleneiodonium
phenylmethylsulfonyl
fluorid
inhibit
furthermor
abl
inhibit
lpsinduc
nitric
oxid
gener
macrophag
aminoguanidin
da
silva
et
al
studi
vivo
antiinflammatori
activ
hinokinin
rat
paw
oedema
reduct
assay
hinokinin
shown
possess
good
antioedema
activ
term
efficaci
dose
depend
manner
dose
mgkg
induc
reduct
similar
indomethacin
dose
antiinflammatori
activ
accompani
analges
effect
demonstr
author
acet
acidinduc
writh
test
mice
compound
produc
high
inhibit
level
algogen
process
immunosuppress
activ
play
import
role
manag
resolv
inflamm
regard
immunosuppress
activ
hinokinin
activ
nfat
transcript
factor
found
activ
lipopolysaccharid
lp
induc
cytokin
product
assay
remark
activ
lymphocyt
transform
assay
tabl
recent
desal
et
al
studi
antiinflammatori
effect
hinokinin
establish
exert
antiinflammatori
effect
via
mechan
lima
et
al
evalu
antiinflammatori
analges
activ
bark
crude
dichloromethan
extract
bced
z
riedelianum
found
bced
abl
reduc
carrageenaninduc
rat
paw
oedema
h
dose
mgkg
inhibit
indometacin
mgkg
one
compon
activ
extract
hinokinin
author
suggest
extract
could
display
antiinflammatori
activ
associ
cox
inhibit
moreov
bced
display
central
analges
activ
hinokinin
show
interest
activ
trypanosoma
cruzi
respons
chaga
diseas
neglect
protozoan
diseas
affect
million
peopl
latin
america
current
two
effect
drug
chaga
diseas
treatment
name
nifurtimox
benznidazol
bzn
caus
seriou
side
effect
therefor
urgent
demand
discoveri
safer
effect
new
therapeut
compound
cruzi
complex
life
cycl
character
sever
development
form
present
vertebr
invertebr
host
parasit
exist
least
three
morpholog
distinct
form
infect
metacycl
blood
trypomastigot
insect
born
epimastigot
replic
vector
intracellular
replic
amastigot
hinokinin
last
year
studi
interest
antitripanosom
compound
de
souza
et
al
testedhinokinin
vitro
free
amastigot
form
strain
cruzi
found
compar
bzn
tabl
view
antitrypanosom
activ
hinokinin
later
select
assay
epimastigot
intracellular
amastigot
form
cruzi
vitro
vivo
assay
see
tabl
vivo
assay
obtain
result
show
treatment
hinokinin
promot
parasitaemia
reduct
parasitaem
peak
benznidazol
display
approxim
parasit
reduct
antitrypanosom
activ
hinokinin
determin
use
mtt
assay
sartorelli
cowork
evalu
trypomastigot
intracellular
amastigot
cruzi
result
shown
tabl
order
studi
toxic
hinokinin
mammalian
cell
sartorelli
also
studi
hinokinin
hemolyt
activ
cytotox
hinokinin
shown
effect
trypomastigot
result
toxic
mammalian
cell
low
parasit
select
select
index
obtain
better
efficaci
promis
lead
compound
toward
intracellular
form
parasit
saraiva
et
al
prepar
investig
effect
new
formul
use
biodegrad
polym
poli
llactidecoglycol
acid
plga
control
releas
hinokinin
treatment
infect
mice
hinokininload
microparticl
abl
provok
signific
decreas
parasitemia
level
compar
observ
untreat
control
furthermor
saraiva
et
al
show
administr
hinokininload
microparticl
abl
reduc
number
parasit
hinokinin
cours
overal
infect
reduct
tissu
parasit
upon
treatment
hinokinin
evalu
vivo
esperandim
cowork
quantifi
enzym
express
clone
strain
cruzi
treatment
mice
infect
cruzi
hinokinin
promot
signific
reduct
tissu
parasit
liver
spleen
heart
compar
data
record
untreat
control
treatment
hinokinin
benznidazol
drug
concentr
mgkg
day
furnish
parasit
reduct
liver
spleen
heart
respect
author
note
differ
oral
intraperiton
administr
rout
former
effect
evalu
organ
bzn
administ
intraperitoneali
effect
spleen
heart
parasit
reduct
later
esperandim
evalu
detail
vivo
therapeut
properti
oral
administ
hinokinin
strain
cruzi
hinokinin
assay
concentr
mgkg
author
observ
hinokinin
mgkg
reduc
number
circul
form
peak
parasitemia
mgkg
karyometri
analysi
show
better
behavior
mgkg
dose
tabl
nonlinear
behavior
two
dose
mgkg
dose
effect
explain
immunomodulatori
respons
hinokinin
exert
well
known
immunosuppress
chronic
infect
patient
lead
diseas
reactiv
high
parasitemia
alreadi
report
hinokinin
act
immunosuppress
compound
see
hinokinin
test
antiplasmodi
activ
sensit
resist
strain
plasmodium
falciparum
hinokinin
respect
chloroquin
show
possess
signific
antimalari
activ
either
strain
hinokinin
studi
bioactiv
sever
microorgan
exampl
silva
et
al
examin
activ
compound
oral
pathogen
enterococcu
faecali
candida
albican
sever
streptococcu
strain
see
tabl
point
data
report
tabl
although
chlorhexidin
much
activ
hinokinin
nevertheless
show
discret
antimicrobi
activ
consid
antibacteri
activ
hinokinin
silva
et
al
evalu
antimycobacteri
activ
other
lignan
hinokinin
show
moder
activ
tuberculosi
mic
valu
equal
inact
kansasii
avium
mic
respect
sever
research
group
studi
antivir
properti
hinokinin
human
hepat
b
viru
hbv
human
immunodefici
viru
hiv
sarsviru
sarscov
case
show
signific
antivir
activ
light
interest
biolog
activ
hinokinin
potenti
use
therapeut
agent
import
investig
mutagen
genotox
activ
recent
resend
et
al
use
ame
comet
assay
assess
safeti
use
hinokinin
drug
comet
assay
chines
hamster
lung
fibroblast
hinokinin
shown
genotox
treatment
hinokinin
associ
known
mutagen
doxorubicin
dxr
lower
concentr
significantli
reduc
dxrinduc
dna
damag
reduct
dna
damag
frequenc
rang
dose
depend
resend
also
show
hinokinin
protect
effect
prevent
clastogen
damag
caus
methyl
methanesulfon
mm
percent
reduct
rang
mutagen
activ
evalu
ame
test
use
salmonella
typhimurium
tester
strain
use
five
differ
concentr
hinokinin
select
basi
preliminari
toxic
test
mutagen
assay
show
induc
increas
number
revert
coloni
rel
neg
control
indic
absenc
mutagen
activ
medola
cowork
studi
mutagen
andor
antimutagen
effect
hinokinin
vivo
use
rat
peripher
blood
micronucleu
test
differ
micronucl
cell
treat
anim
control
signif
demonstr
genotox
effect
coexposit
anim
hinokinin
dxr
show
signific
reduct
frequenc
mnpce
micronucl
polychromat
erythrocyt
howev
protect
effect
hinokinin
dose
depend
hinokinin
test
sever
biolog
activ
antispasmod
effect
electr
induc
eci
acetylcholin
induc
achi
histamin
induc
contract
isol
guineapig
ileum
use
channel
blocker
verapamil
posit
control
hinokinin
significantli
inhibit
eci
achi
contract
neurit
outgrowthpromot
activ
cell
hinokinin
isol
c
obtusa
presenc
absenc
nerv
growth
factor
ngf
ngml
studi
hinokinin
show
potent
neurit
outgrowthpromot
activ
cultur
ngf
without
ngf
nowaday
well
establish
neuron
glia
develop
regul
neurotransmitt
monoamin
neurotransmitt
dopamin
norepinephrin
serotonin
posit
action
classic
growth
factor
glutam
gaba
acid
downregul
prolifer
agent
hinokinin
show
neuroprotect
activ
glutam
induc
neurotox
primari
cultur
rat
cortic
cell
percentag
protect
dizociplin
maleat
noncompetit
antagonist
nmda
nmethyldaspart
receptor
one
glutam
receptor
show
percentag
protect
furthermor
timpl
et
al
demonstr
hinokinin
select
inhibitor
human
dopamin
norepinephrin
transport
noncompetit
manner
low
affin
serotonin
transport
cytochrom
cyp
enzym
play
import
role
phase
oxid
metabol
widw
rang
xenobiot
human
isoform
cyp
identifi
among
other
methylenedioxyphenyl
compound
well
known
inhibit
cytochrom
p
cyp
reaction
form
stabl
complex
cyp
enzym
reason
sever
natur
compound
incorpor
structur
featur
studi
inhibitori
activ
cyp
enzym
hinokinin
contain
two
methylenedioxyphenyl
ring
molecul
show
potent
cyp
inhibit
later
usia
et
al
show
hinokinin
activ
inhibit
time
concentr
nadphdepend
manner
via
format
metabolit
intermedi
complex
therefor
attent
paid
probabl
drugdrug
interact
hinokinincontain
prepar
molecul
substrat
lignan
repres
import
biolog
activ
class
secondari
metabolit
studi
biolog
activ
compound
antioxid
anticanc
properti
howev
recent
year
import
metabolit
especi
hinokinin
potenti
antichagas
agent
point
addit
hinokinin
shown
nongenotox
possess
neuroprotect
effect
reason
hinokinin
emerg
promis
compound
broad
interest
biolog
activ
